Concordantly, antisense oligonucleotides against the long transcript crossing the domain result in the activation of the paternal UBE3A gene, and such an approach is currently used in different clinical trials to treat Angelman Syndrome, a neuro-behavioural syndrome caused by loss of UBE3A expression [44,45]. Here, UBE3A is linked to Angelman syndrome.